Recombinant Porphyromonas gingivalis Gingipain R2 (rgpB) is produced in an E. coli expression system, featuring a full-length mature protein from amino acids 230 to 736. The protein includes a C-terminal 10xHis tag for efficient purification and detection. Its purity exceeds 85% as confirmed by SDS-PAGE, which appears to provide a reliable reagent for research applications focused on this bacterial protease.
Gingipain R2 is a protease from Porphyromonas gingivalis, an important bacterium in oral health research. This cysteine protease likely plays a crucial role in bacterial virulence by processing protein substrates that contribute to periodontal tissue degradation. It represents a promising target for studies on bacterial pathogenesis and potential therapeutic interventions in periodontal disease.
Potential Applications
Note: The applications listed below are based on what we know about this protein's biological functions, published research, and experience from experts in the field. However, we haven't fully tested all of these applications ourselves yet. We'd recommend running some preliminary tests first to make sure they work for your specific research goals.
The P. gingivalis Gingipain R2 is a cysteine protease that requires precise folding, correct disulfide bond formation, and potentially specific activation (many proteases are synthesized as zymogens) for enzymatic activity. While the C-terminal His tag is less likely to interfere with the active site than an N-terminal tag, E. coli may not facilitate the proper folding environment or post-translational modifications needed for this complex bacterial protease. Without experimental validation, it cannot be assumed to be correctly folded or bioactive.
1. Antibody Development and Immunological Studies
This application is generally suitable. The recombinant rgpB can serve as an immunogen for antibody production since antibodies often recognize linear epitopes regardless of protein folding. The C-terminal His tag facilitates purification. However, antibodies generated may not recognize conformational epitopes of the native, properly folded, and activated Gingipain R2. Validate antibody specificity against native P. gingivalis proteins or culture supernatants containing the active protease.
2. Protein-Protein Interaction Studies
Use with extreme caution. The His tag enables pull-down assays, but if the protein is misfolded or inactive, it may not interact with physiological partners (e.g., host proteins or bacterial substrates) correctly. Non-specific binding or false negatives are likely. Any identified interactions must be validated using active, native Gingipain R2 from P. gingivalis culture supernatants.
3. Biochemical Characterization and Enzyme Kinetics
This application is only valid if the recombinant rgpB is first confirmed to be enzymatically active. Without activity verification, kinetic studies are meaningless. If active, standard protease assays (e.g., using synthetic substrates like BApNA) can determine kinetic parameters. However, the specific activity may differ from the native enzyme due to the His tag or folding differences. Always compare with native gingipain activity when possible.
4. Structural and Biophysical Analysis
Suitable for basic biophysical characterization (e.g., circular dichroism for secondary structure, dynamic light scattering for aggregation state). However, structural data may not reflect the native, active conformation of Gingipain R2 if the protein is misfolded. The His tag may also influence biophysical properties. Interpret data cautiously and avoid extrapolating to functional mechanisms without activity correlation.
Final Recommendation & Action Plan
Before using this recombinant rgpB for any functional application, it is crucial to validate its folding and enzymatic activity. First, perform a simple protease activity assay using a known Gingipain substrate (e.g., BApNA) to confirm catalytic function. If inactive, investigate whether in vitro activation (e.g., by proteolytic cleavage) is required. For antibody production, proceed but validate antibodies against native P. gingivalis gingipains. Avoid interaction studies or kinetic characterization without confirmed activity. If activity is validated, the protein can be used for limited functional studies, but always include appropriate controls (e.g., known gingipain inhibitors). For reliable structural or functional insights, consider alternative expression systems (e.g., P. gingivalis itself or eukaryotic systems) that may better support correct folding and activation.
-SDS.jpg)
